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Abstract
Background Geographic variation and temporal trends in
the epidemiology of esophageal and gastric cancers vary
according to both tumor morphology and organ subsite.
This study compares 1-year survival of gastric and
esophageal cancers between two distinct populations:
British Columbia (BC), Canada, and Ardabil, Iran.
Methods Data for invasive primary esophageal and gastric
cancer patients were obtained from the population-based
cancer registries for BC and Ardabil. The relative survival
rate was calculated using WHO Statistical Information
System (WHOSIS) life-tables for each country. Chi-square
and Fisher’s exact tests were used to compare survival
differences between BC and Ardabil. T-tests, chi-square
tests, and Fisher’s exact test were used to compare patient
characteristics and tumor factors between the populations.
Results The overall 1-year age-standardized relative sur-
vivals for gastric cancer were 48% and 21% in BC and
Ardabil, respectively (p<0.01). The overall 1-year age-
standardized relative survival for esophageal cancer was
33% and 17% in BC and Ardabil, respectively (p<0.05).
Overall and separately for each gender, age group, tumor
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DOI 10.1007/s12029-010-9228-ylocation, and histology, there was greater 1-year survival of
the gastric cancer patients in BC compared to Ardabil. For
esophageal cancer; patients under age 65, patients with
tumors in the middle or upper third of esophagus, and
patients with squamous cell carcinoma had significantly
better survival in BC than in Ardabil.
Conclusion Findings of this study point to differences in
disease characteristics and patient factors, not solely differ-
ences in healthcare systems, as being responsible for the
survival difference in these populations.
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Introduction
Geographic variation and temporal trends in the epidemi-
ology of esophageal and gastric cancers vary according to
tumor morphology and organ subsite [1]. Both diseases are
among the deadliest forms of cancer. Gastric cancer
incidence and mortality have fallen dramatically over the
past 70 years in western countries, but it is the fourth most
commonly diagnosed cancer and the second most common
cause of cancer-related death worldwide [2]. The majority
of esophageal carcinoma patients in the world die within a
year of diagnosis and only 8–20% are alive after 5 years
[3]. Gastric and esophageal cancers are relatively infrequent
in Canada, but common in Iran [4].
This study compares 1-year survival of gastric and
esophageal cancers between the populations of British
Columbia (BC), Canada, and Ardabil, Iran. We chose BC and
Ardabil because both areas have high-quality population-based
cancerregistries.TheBCCancerRegistryhasbeeninexistence
since 1969 (www.bccancer.bc.ca/HPI/CancerStatistics,
accessed November 4, 2009), and the Ardabil Cancer Registry
is the first such registry in the Islamic Republic of Iran [5].
This study does not compare survival rates for different types
of esophageal or gastric cancer within Ardabil or within BC.
Methods
Data for invasive primary esophageal and gastric cancer
patients diagnosed in 2004 were obtained from the cancer
registries for BC and Ardabil. For the BC registry,
completeness of case ascertainment was 86.8% and
completeness of other information was 99.8% [6]. For the
Ardabil registry, overall completeness was 89% based on
reports from pathology centers, identity information,
demographic information and percentage of coded cancer
cases [7]. Dates in the Ardabil registry were converted to
equivalent values in the western calendar. For both
registries, the topography and histology of cases were
coded according to the International Classification of
Diseases for Oncology, Third Edition (ICD-O) [8]. Similar
methods were used for the collection and classification of
breast cancer data from BC and Ardabil data in an earlier
report [9]. Esophageal cancers were grouped into four
anatomic subsites: upper third (ICD-O codes C15.0–
C15.3), middle third (C15.4), lower third and overlapping
lesions (C15.5), and unknown (C15.8 and C15.9). Gastric
cancers were grouped into three anatomic subsites:
proximal third (i.e., cardia) in the gastroesophageal
junction or upper third of the stomach (C16.0 and
C16.1), distal stomach or lower two thirds of the stomach
(C16.2–C16.7), and unknown or unspecified/overlapping
lesion (C16.8 and C16.9). Histological categories for
esophageal cancers were squamous cell carcinoma (ICD-
O codes 8050–8082), adenocarcinoma (8140–8573), and
others (mainly 8000–8020). Gastric cancers were catego-
rized as diffuse or intestinal according to the Lauren
classification system [10]. Diffuse gastric tumors are
defined by ICD-O histology codes 8142, 8145, and 8490
[11]; other gastric tumors are defined as intestinal.
In BC, the vital status and date of death for cancer
patients is routinely collected from government statistics.
At least 1 year of follow-up information was available
for each patient in BC. In Ardabil, information on a
patient’s survival and date of death was obtained by
interviewing cases or their families. Interviews were
conducted by members of the Ardabil Cancer Registry
whenever possible. The deathr e g i s t r yi nA r d a b i lw a s
used to confirm this information and obtain data for
patients who could not be interviewed. Based on this
approach, 83.3% of Ardabil patients had completed
1-year follow-up information.
Survival time was defined as the time between cancer
diagnosis and death. The relative survival rate [12] was
calculated for various subgroups of each population using
WHO Statistical Information System (WHOSIS) life-tables
for each country [13]. Chi-square and Fisher’s exact tests
were used to compare differences in 1-year survival
proportions between BC and Ardabil. T tests, chi-square
tests and Fisher’s exact test were used to compare patient
characteristics and tumor factors between the populations. P
values less than 0.05 were considered statistically signifi-
cant. Other p values were denoted non-significant (NS).
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In 2004, 357 and 261 cases of gastric cancer were
diagnosed in BC and Ardabil, respectively. Characteristics
of the cases are summarized in Table 1. The mean ages of
patients were 69.1 years in BC and 66.1 years in Ardabil
(p<0.01). Women comprised about one third of gastric
cancer patients in both BC and Ardabil (NS). Approxi-
mately 34.5% of gastric cancer cases (49% of cases with
known topography) in BC and 41.8% (60% of cases with
known topography) in Ardabil were diagnosed with
proximal disease (p<0.05). Adenocarcinoma was the
predominant histological type of gastric tumor, accounting
for 87.4% and 79.7% of cases in BC and Ardabil,
respectively (p<0.01). About 16.0% of gastric tumors in
BC and 30.3% in Ardabil were the diffuse type (p<0.05).
In 2004, 232 and 124 cases of esophageal cancer were
diagnosed in BC and Ardabil, respectively. Characteristics
of cases are summarized in Table 2. The mean age of cases
was 69.7 years in BC and 63.3 years in Ardabil (p<0.01).
Women accounted for about one third of cases in BC and
half of cases in Ardabil (p<0.01). Most tumors in BC cases
were located in the lower third of the esophagus, while the
lower and middle thirds of the esophagus had nearly equal
incidence in Ardabil (p<0.01). Adenocarcinoma was the
leading type of tumor in BC cases (50% of all cases), while
only 10% of cases in Ardabil had this histology type
(p<0.01).
Figures 1 and 2 show the overall 1-year age-standardized
relative survival of gastric and esophageal cancers in BC
and Ardabil. Details of the survival rates for gastric and
esophageal cancer in BC and Ardabil are shown in Tables 3
and 4. Overall and separately for each gender, age group,
tumor location, and histology, there was greater 1-year
survival of gastric cancer patients in BC compared to
Ardabil. Patients under age 65, patients with tumors in the
middle or upper third of the esophagus, and patients with
squamous cell carcinoma had significantly better esopha-
geal cancer survival in BC than in Ardabil. Table 3 shows
substantial differences for age and tumor location groups
within gastric cancer patients in BC that are not seen in Table 1 Gastric cancer patients in BC (Canada) and Ardabil (Iran)
British Columbia Ardabil
Gender
Women 119 (33.3%) 75 (28.7%)
Men 238 (66.7%) 185 (70.9%)
Unknown 1 (0.4%)
Age group
Less than 65 118 (33.1%) 108 (41.4%)
65 or more 239 (66.9%) 153 (58.6%)
Location
Distal 127 (35.6%) 72 (27.6%)
Proximal 123 (34.5%) 109 (41.8%)
NOS/overlapping lesion 107 (30.0%) 80 (30.7%)
Lauren classification
a
Intestinal 262 (84.0%) 145 (69.7%)
Diffuse 50 (16.0%) 63 (30.3%)
NOS not otherwise specified
aAdenocarcinomas only
Table 2 Esophageal cancer patients in BC (Canada) and Ardabil
(Iran)
British Columbia Ardabil
Gender
Women 64 (27.6%) 61 (49.2%)
Men 168 (72.4%) 62 (50.0%)
Unknown 1 (0.8%)
Age group
Less than 65 76 (32.8%) 67 (54.0%)
65 or more 156 (67.2%) 57 (46.0%)
Tumor location
Upper third 23 (9.9%) 6 (4.8%)
Middle third 40 (17.2%) 35 (28.2%)
Lower third 112 (48.3%) 38 (30.6%)
NOS/overlapping lesion 57 (24.6%) 45 (36.3%)
Tumor histology
Squamous cell carcinoma 88 (37.9%) 89 (71.8%)
Adenocarcinoma 116 (50.0%) 13 (10.5%)
Other 28 (12.1%) 22 (17.7%)
NOS not otherwise specified
Fig. 1 Overall 1-year age-standardized survival rates for gastric
cancer cases in Ardabil (Iran) and British Columbia (Canada). Bars
are ± standard error
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had substantial survival differences for age and tumor
location groups that were not meaning in BC (Table 4).
Discussion
Based on available registry and follow-up information, this
study compares 1-year survival of gastric and esophageal
cancer in two populations. Results indicate major differ-
ences and some interesting similarities between the pop-
ulations. In general, overall 1-year relative survival was
better in BC than Ardabil. There were significant differ-
ences between the populations in gastric cancer survival
according to patient gender, age, tumor location, and tumor
histology. For esophageal cancer; patients under age 65,
patients with tumors in the middle or upper third of the
esophagus, and patients with squamous cell carcinoma had
significantly better survival in BC than in Ardabil. Survival
differences between the populations might be based on
other tumor-related factors, other patient characteristics,
cancer control measures, and treatment factors.
Stage at diagnosis is likely the main tumor-related factor
affecting a patient’s prognosis, and stage at diagnosis
determines the course of a patient’s treatment [14].
Unfortunately, we could not include stage in our analysis
because both cancer registries provided only limited
information about it. Cell histology is another tumor-
related factor that might affect patient survival [14]. In this
study, the Lauren classification (based on tumor histology)
did not have prognostic significance for 1-year survival of
gastric cancer patients in either population. Several clinical
studies report better survival for adenocarcinoma of
esophagus [15–17], but we did not observe this. In both
BC and Ardabil, tumor histology did not have a substantial
influence on the survival of esophageal cancer patients. In
Ardabil, tumors in the middle third of the esophagus were
associated with worse survival than tumors located in the
lower third. In Ardabil, the low number of cases with a
tumor in the esophagus’ upper third makes it difficult to
derive any meaningful conclusion concerning this group.
This result is consistent with a recent report from Turkey
[18]. However, results from BC and other North American
studies [1, 3] indicate that survival of patients with cancers
in the upper, middle, and lower third of the esophagus are
similar.
Ethnicity has been suggested to be a possible prognosis
factor for cancer in upper GI tract [19, 20]. BC has an
ethnically diverse population. The 2006 census reported
that only 52% of people living in BC at that time had a
single ethnic origin [21]. In contrast, the population of
Ardabil is homogeneous, with 95% being of Azeri ethnic
background, which is of Aryan Caucasoid ancestry [5].
Family history also has been shown to be a prognostic
factor in gastric and esophageal cancer. Gastric cancer
patients with a family history of this tumor have unique
clinicopathologic characteristics [22]. Poor survival among
young patients from Ardabil could be explained by the
presence of a higher proportion of familial cases of the
disease. This is consistent with reports from other high-
incidence areas [23]. Also, the high incidence of diffuse
gastric cancer in the ethnically homogeneous Ardabil
Fig. 2 Overall 1-year age-standardized survival rates for esophageal
cancer cases in Ardabil (Iran) and British Columbia (Canada). Bars
are ± standard error
BC Ardabil p
Gender Male 0.48±0.07 0.18±0.09 <0.01
Female 0.46±0.09 0.26±0.08 <0.01
Age Less than 65 0.62±0.07 0.22±0.09 <0.01
65 or more 0.41±0.04 0.20±0.05 <0.01
Tumor Location Distal 0.61±0.07 0.23±0.06 <0.01
Proximal 0.45±0.08 0.19±0.06 <0.01
Lauren Classification
a Intestinal 0.48±0.07 0.18±0.04 <0.01
Diffuse 0.50±0.10 0.24±0.04 <0.05
Table 3 One-year relative
survival for gastric cancer
patients in BC (Canada) and
Ardabil (Iran)
Values are age-standardized
rates ± standard error
aAdenocarcinomas only
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mutations in the E-cadherin gene that underlie hereditary
diffuse gastric cancer [24].
Treatment is likely to be the greatest determinant of
cancer patients’ survival, and province-wide treatment
guidelines in BC result in nearly uniform treatment (http://
www.bccancer.bc.ca/HPI/CancerManagementGuidelines/
Gastrointestinal/default.htm). Patient characteristics include
inherent and demographic characteristics such as age,
sex, ethnicity, physical performance status, comorbidity, and
immune status. These variables are usually unrelated to the
presence of tumor but may have a profound impact on
treatment choices [18]. The general treatment for esophageal
and respectable gastric cancer was surgery. Some patients
also received radiation and chemotherapy depending on the
stage of disease [1]. In Ardabil, guidelines do not exist and
treatment is not uniform. Based on previous reports, only
28% of patients with gastric and esophageal cancer in
Ardabil received curative resectional surgery and about 25%
of patients did not receive any treatment [25].
This study does not compare the distribution of patient/
tumor characteristics within either the BC or Ardabil
population, but it is obvious that the distributions are
different. One of the interesting differences between BC
and Ardabil is the survival pattern for proximal and distal
gastric cancers. In BC, patients with proximal gastric
tumors had poorer survival than patients with distal ones.
In Ardabil, there was very little difference between survival
for proximalanddistalgastric cancers.InBC,onlyabout one-
third of tumors occurred in the middle and upper third of the
esophagus. In Ardabil, more than half of tumors with known
topologywerelocatedinthisanatomicregion.Morementhan
women had gastric and esophageal cancers in BC; however,
the incidence of esophageal cancer in Ardabil seemed
independent of gender (i.e., the same in both sexes).
The strength of this study was the availability of
population-based data with details of tumor histology
and pathology. This study’s limitations include the lack
of complete staging information, incomplete follow-up
data, and the relatively large proportion of esophageal
tumors with unspecified histology. Differences in the
quality of registry data between two populations could
also have influenced survival comparisons. As noted in
the Report of National Cancer Registration in Iran [7],
there are challenges in interpreting registry information
regarding the health care system in Iran. There is vast,
uncontrolled population movement in and out of Ardabil,
an uncoordinated medical services system, and inconsis-
tent referrals to different centers for diagnosis and
treatment [7]. It is also possible that patients with better
socioeconomic status are referred to better medical
facilities in central cities.
Population-based survival studies cannot assess specific
treatments but can quantify the effect of cancer control
measures at the population level [26]. Neither BC nor
Ardabil has a screening program for gastric and esophageal
cancers. In BC, these cancers are infrequent and feasibility
of screening is questionable. However, Ardabil has the
highest rates of gastric and esophageal cancers in the world,
and a screening program should be considered.
Conclusion
Gastric and esophageal cancers are heterogeneous diseases,
but they share important features. They remain clinically
asymptomatic until late in the disease process with
consequent poor prognoses and high mortality rates. This
study points to differences in disease characteristics and
patient factors, not solely differences in healthcare systems,
as being responsible for the survival difference in these
populations. Even so, the outcomes of these cancers are
poor for both populations, and improvements in diagnosis
and management are urgently needed.
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BC Ardabil p
Gender Male 0.32±0.07 0.25±0.1 NS
Female 0.34±0.07 0.18±0.06 NS
Age Less than 65 0.44±0.11 0.19±0.06 <0.01
65 or more 0.27±0.03 0.26±0.05 NS
Tumor Location Upper third 0.50±0.14 0 <0.05
Middle third 0.42±0.12 0.1±0.05 <0.05
Lower third 0.33±0.10 0.33±0.09 NS
Histology SCC 0.40±0.10 0.20±0.06 <0.01
Adenocarcinoma 0.34±0.08 0.38±0.16 NS
Table 4 One-year relative
survival for esophageal cancer
patients in BC (Canada) and
Ardabil (Iran)
Values are age-standardized
rates ± standard error
NS Non-significant
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